Press coverage about Ophthotech Corporation (NASDAQ:OPHT) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ophthotech Corporation earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 47.3140341390666 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- 3 Things In Biotech You Should Learn Today: August 16, 2017 (seekingalpha.com)
- Ophthotech Announces Results from Third Phase III Trial of Fovista - Drug Discovery & Development (dddmag.com)
- AbbVie Inc. (ABBV) noted a price change of -0.68% and Ophthotech Corporation (OPHT) closes with a move of 0.37% - Stocks Gallery (stocksgallery.com)
- Ophthotech’s Fovista Combo Regimen Disappoints in Phase III - Nasdaq (nasdaq.com)
- Fovista fails again in wet AMD (thepharmaletter.com)
Shares of Ophthotech Corporation (OPHT) traded up 1.82% during mid-day trading on Friday, hitting $2.80. 287,754 shares of the company traded hands. The stock’s market capitalization is $100.64 million. The firm has a 50-day moving average of $2.62 and a 200-day moving average of $3.10. Ophthotech Corporation has a one year low of $2.24 and a one year high of $59.99.
Ophthotech Corporation (NASDAQ:OPHT) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.45. The firm had revenue of $1.66 million during the quarter, compared to the consensus estimate of $1.38 million. During the same quarter last year, the business posted ($0.85) earnings per share. Ophthotech Corporation’s revenue was down 94.1% compared to the same quarter last year. On average, equities analysts predict that Ophthotech Corporation will post $0.29 earnings per share for the current year.
Separately, Zacks Investment Research raised shares of Ophthotech Corporation from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research report on Tuesday, May 2nd. Twelve research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $54.47.
TRADEMARK VIOLATION WARNING: This piece of content was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/18/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-ophthotech-corporation-opht-share-price-updated.html.
In other news, Chairman David R. Guyer sold 17,678 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $2.58, for a total value of $45,609.24. Following the completion of the transaction, the chairman now directly owns 37,692 shares in the company, valued at $97,245.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 34,609 shares of company stock valued at $89,249 over the last 90 days. 2.00% of the stock is owned by company insiders.
About Ophthotech Corporation
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
